Royal Bank Of Canada Verastem, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.39 - $0.71 $5,052 - $9,197	-12,954 Reduced 4.1%	303,370 $127,000
Q4 2022 Feb 14, 2023	SELL	$0.33 - $10.44 $2,824 - $89,355	-8,559 Reduced 2.63%	316,324 $126,000
Q3 2022 Nov 14, 2022	BUY	$0.92 - $11.16 $1,497 - $18,168	1,628 Added 0.5%	324,883 $276,000
Q2 2022 Aug 15, 2022	BUY	$1.02 - $1.83 $318,908 - $572,158	312,655 Added 2949.58%	323,255 $375,000
Q1 2022 May 16, 2022	SELL	$1.06 - $2.1 $29,440 - $58,325	-27,774 Reduced 72.38%	10,600 $15,000
Q4 2021 Feb 14, 2022	BUY	$2.05 - $3.2 $26,217 - $40,924	12,789 Added 49.99%	38,374 $79,000
Q3 2021 Nov 15, 2021	BUY	$2.54 - $4.07 $34,927 - $55,966	13,751 Added 116.2%	25,585 $79,000
Q2 2021 Aug 16, 2021	BUY	$2.57 - $4.85 $30,413 - $57,394	11,834 New	11,834 $48,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.09B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.